anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Hepatic fibrosis (HF) is a common pathological feature of chronic hepatic diseases. We aimed to illuminate the significance of amniotic mesenchymal stem cells (AMSCs)-derived extracellular vesicles (AMSCs-EVs) in HF.
METHODS: Human AMSCs-EVs were isolated and identified. HF mice were constructed and treated with EVs. The fibrosis was observed by staining experiments and Western blot (WB) assay. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and hepatic hydroxyproline (Hyp) were detected to confirm liver function. For the in vitro experiments, human hepatic stellate cells were induced with transforming growth factor-β and treated with EVs. To measure the degree of HF, the expression of alpha-smooth muscle actin (α-SMA) and Collagen I was detected by WB assay, and cell proliferation was detected by cell counting kit 8 assay. The levels of miR-200a, Zinc finger E-box binding homeobox 1 (ZEB1), and phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3) were detected by WB and real-time quantitative polymerase chain reaction. The binding of ZEB1 to PIK3R3 and miR-200a to ZEB1 was analyzed by chromatin immunoprecipitation and dual luciferase assays to validate their relationships.
RESULTS: Human AMSCs and AMSCs-EVs were obtained. Serum ALT, AST, TBIL, and hepatic Hyp were increased, implying the fibrosis degree was aggravated in HF mice, which was decreased again after EV treatment. EVs inhibited HF degree by reducing α-SMA and Collagen I and promoting cell proliferation. AMSCs-EVs delivered miR-200a into hepatocytes, which up-regulated miR-200a expression, inhibited ZEB1 expression, and reduced its enrichment on the PIK3R3 promoter, therefore inhibiting PIK3R3 expression and alleviating HF. Overexpression of ZEB1 or PIK3R3 attenuated the anti-fibrotic effect of AMSCs-EVs.
CONCLUSION: Human AMSCs-derived EVs mediated miR-200a delivery and inhibition of intracellular ZEB1/PIK3R3 axis to exert anti-fibrosis effects.
The invention relates to a new dry concentrate for the production of medical solutions, more particularly dialysis solutions, which comprise electrolyte and buffer components and an osmotic agent, said concentrate comprising magnesium carbonate rather than magnesium chloride. The use of magnesium carbonate as the electrolyte avoids the formation of slurries. The use of anhydrous glucose as an osmotic agent, and optionally spatial separation of this osmotic agent from the other components, also avoids the occurrence of "caking" in the concentrate. The occurrence of "caking" is also improved by charging the sodium hydrogencarbonate buffer component together with sodium chloride and in isolation from all other components. This concentrate is particularly suitable for use in multichamber pouch systems. The concentrate is notable for good dissolution capacity and improved storage stability.
AIMS: Venous thromboembolism (VTE) is a potential complication of foot and ankle surgery. There is a lack of agreement on contributing risk factors and chemical prophylaxis requirements. The primary outcome of this study was to analyze the 90-day incidence of symptomatic VTE and VTE-related mortality in patients undergoing foot and ankle surgery and Achilles tendon (TA) rupture. Secondary aims were to assess the variation in the provision of chemical prophylaxis and risk factors for VTE.
METHODS: This was a multicentre, prospective national collaborative audit with data collection over nine months for all patients undergoing foot and ankle surgery in an operating theatre or TA rupture treatment, within participating UK hospitals. The association between VTE and thromboprophylaxis was assessed with a univariable logistic regression model. A multivariable logistic regression model was used to identify key predictors for the risk of VTE.
RESULTS: A total of 13,569 patients were included from 68 sites. Overall, 11,363 patients were available for analysis: 44.79% were elective (n = 5,090), 42.16% were trauma excluding TA ruptures (n = 4,791), 3.50% were acute diabetic procedures (n = 398), 2.44% were TA ruptures undergoing surgery (n = 277), and 7.10% were TA ruptures treated nonoperatively (n = 807). In total, 11 chemical anticoagulants were recorded, with the most common agent being low-molecular-weight heparin (n = 6,303; 56.79%). A total of 32.71% received no chemical prophylaxis. There were 99 cases of VTE (incidence 0.87% (95% CI 0.71 to 1.06)). VTE-related mortality was 0.03% (95% CI 0.005 to 0.080). Univariable analysis showed that increased age and American Society of Anesthesiologists (ASA) grade had higher odds of VTE, as did having previous cancer, stroke, or history of VTE. On multivariable analysis, the strongest predictors for VTE were the type of foot and ankle procedure and ASA grade.
CONCLUSION: The 90-day incidence of symptomatic VTE and mortality related to VTE is low in foot and ankle surgery and TA management. There was notable variability in the chemical prophylaxis used. The significant risk factors associated with 90-day symptomatic VTE were TA rupture and high ASA grade.
Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of treating pimple by including a combination of an extract of Eriobotorya japonica Lindl., and one or more of a keratin softening and releasing agent, an antiinflammatory agent, an antibacterial and antifungal agent, a sebum suppressing and absorbing agent and a protease inhibitor. SOLUTION: This medicine comprises one or more of a keratin softening and releasing agent, an antiinflammatory agent, an antibacterial and antifungal agent, a sebum suppressing and absorbing agent and a protease inhibitor and an extract of Eriobotorya japonica Lindl., as active ingredients. The keratin softening and releasing agent includes a betaine, sulfur, salicylic acid, etc., and its amount is 0.001-5 wt.% in the whole amount. The antiinflammatory agent includes glycyrrhizinic acid, indomethacin, etc., and its amount is 0.01-5 wt.%. The antibacterial and antifungal agent includes sulfur, hinokitiol, etc., and its amount is 0.01-5 wt.%. The sebum suppressing and absorbing agent includes an essence of burdock, etc., and its amount is 0.01-10 wt.%. The protease inhibitor includes tranexamic acid, etc., and is amount is 0.01-10 wt.%.  The amount of the extract of Eriobotorya japonica Lindl. is 0.01-10 wt.%. Consequently pimple can be excellently treated under mild conditions to skin without causing hormone-like adverse effects.
All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
Short peptides having biological and therapeutic activity are disclosed. Specifically, the activity of the disclosed peptides is directed to reducing or protecting against mutagen-induced cellular/tissue toxicity (i.e., chemopreventive). For example, the disclosed peptides protect against skin toxicity and/or mutagenesis that occurs from ultraviolet (UV) light exposure. The disclosed peptides also block the activation of certain cell cycle regulatory proteins such as Chk2. An example of such a peptide is Ser-Leu-Tyr-Gln-Ser (SEQ ID NO: 10). The disclosed peptides are also useful for methods of reducing or protecting against cellular toxicity and mutation accumulation that would otherwise occur following mutagen exposure. One such method is drawn to applying a peptide to the skin to prevent or reduce mutagenic damage resulting from UV light (e.g., sunlight) exposure.
Novel organic compounds and metal ion-containing amino acid chelates are described which are useful in solid phase synthesis of polypeptides and as magnetic resonance imaging (MRI) enhancing agents. The present invention also relates to a convenient and straightforward method to synthesize a metal-ligating amino acid suitable as MRI enhancing agents or for introducing a strong metal binding site at any chosen position in a peptide. Some compounds are designed to be compatible with N-α-Fmoc peptide synthesis strategy, and can easily be prepared on large scale. Thus, flexible linkers of different lengths and containing various structures can be placed between the α-carbon backbone of peptides and metal binding moieties. These peptides will provide a variety of affinity cleaving reagents which can be directed against protein or nucleic acid targets. Therefore, these molecules can serve as an important tool to study protein folding, protein-protein and protein-nucleic acid interactions.
Biopsy for tissue immune profile if archived tissue not available. Folfirinox plus Panitumumab (if RAS/BRAF) infusion for 3 cycles followed by a repeat biopsy for a second tissue immune profiling. Folfirinox plus Panitumumab (if RAS/BRAF positive) and CEND1 infusion for 3 cycles. Seventy-two hours after last infusion participant will have surgery.
Ligand-conjugated oligomeric compounds are described wherein ligands are conjugated to one or more sites on an oligomeric compound including the 2'-, 3'-, 5'-, nucleobase and internucleotide linkage sites. The ligand can be attached via an optional linking group. Ligands are selected for conjugation that bind to one or more cellular, serum or vascular proteins imparting enhanced pharmacokinetic properties to the resulting ligand-conjugated oligomeric compounds. Also provided are methods for increasing the concentration of an oligonucleotide in serum and methods for increasing the capacity of serum for an oligonucleotide. Further, methods for increasing the binding of an oligonucleotide to a portion of the vascular system is described. Also provided are methods for promoting cellular uptake of an oligonucleotide in cells.
INTRODUCTION: Perioperative glycaemic control is important. However, the complexity of guidelines for perioperative diabetes management is complicated due to different and novel antihyperglycaemic medications, limited procedure-specific data and lack of data from implemented fast-track regimens which otherwise are known to reduce morbidity and glucose homeostasis disturbances. Consequently, outcome in patients with diabetes mellitus (DM) after surgery and the influence of perioperative diabetes management on postoperative recovery remains poorly understood.
METHODS AND ANALYSIS: A prospective observational multicentre study involving 8 arthroplasty centres across Denmark with a documented implemented fast-track programme (median length of hospitalisation (LOS) 1 day). We will collect detailed perioperative data including preoperative haemoglobin A1c and antidiabetic treatment in 1400 unselected consecutive patients with DM undergoing hip and knee arthroplasty from September 2022 to December 2025, enrolled after consent. Follow-up duration is 90 days after surgery. The primary outcome is the proportion of patients with DM with LOS >4 days and 90-day readmission rate after fast-track total hip arthroplasty (THA), total knee arthroplasty (TKA) and unicompartmental knee arthroplasty (UKA). The secondary outcome is the association between perioperative diabetes treatment and LOS >2 days, 90-day readmission rate, other patient demographics and Comprehensive Complication Index for patients with DM after THA/TKA/UKA in a fast-track regimen.
ETHICS AND DISSEMINATION: The study will follow the principles of the Declaration of Helsinki and ICH-Good Clinical Practice guideline. Ethical approval was not necessary as this is a non-interventional observational study on current practice. The trial is registered in the Region of Southern Denmark and on ClinicalTrials.gov. The main results and all substudies of this trial will be published in peer-reviewed international medical journals.
TRIAL REGISTRATION NUMBER: NCT05613439.
Women who have a diagnosis of gestational diabetes (GDM) or type 2 diabetes (T2DM) and who report food insecurity using the Hunger Vital Signs Screener will be recruited to participate in a comparative study across two urban communities. One arm will receive a grocery prescription program from Instacart Health to be spent on eligible healthy food items based on My Diabetes Plate. The other arm will receive 10 frozen medically tailored meals delivered to their door each week. The meals are based on diabetes guidelines and are culturally appropriate. Meals are created by a local nonprofit food pantry, Dare to Care, in Louisville, Kentucky and delivered via a partnership with Door Dash - Project Dash. Women will be recruited initially from a registered nurse who works at the clinic sites. The study team will then enroll participants after eligibility screening and conduct further onboarding into the food as medicine package based on locations.
The invention discloses a febrifuge, and belongs to the medicinal field. The febrifuge is used for treating typhoid, malaria and influenza, and the odorous breath in high fever. After the febrifuge is taken, the high fever gradually is brought down, the body temperature can decline, and the odor disappears. The febrifuge is a secret prescription handed down from ancestors; and above 300 years of folk treatment practices prove that the febrifuge can release the pains of patients within a short period of time to reach thorough rehabilitation without damaging the human bodies. The composition of the febrifuge comprises the stem, the leaf and the root of honeysuckle, and another medicine. The febrifuge which comprises two medicines has the functions of heat clearing, detoxification and sterilization. The febrifuge can sterilize, is nontoxic, and can clean the heat and the toxicity in the stomach, so the febrifuge has a special effect on the high fever. The effect of the febrifuge disclosed in the invention is better than the effects of modern medicines. The febrifuge has a good effect on the above disease conditions, especially the avian influenza and the typhoid.
Apparatus (20) is provided for implantation into a body of a subject, including isolated functional cells (28). At least one first barrier (22) having a first molecular weight cutoff is disposed with respect to the functional cells so as to protect the functional cells from components disposed within body fluid of the subject having molecular weights higher than the first cutoff. Photosynthetic elements (26) are disposed with respect to the functional cells so as to provide oxygen thereto. At least one second barrier (24) has a second molecular weight cutoff that is lower than the first cutoff. The second barrier is disposed with respect to the photosynthetic elements so as to protect the photosynthetic elements from components disposed within the body fluid of the subject having molecular weights higher than the second cutoff. Other embodiments are also described.
A system which includes one or more processors and a memory including instructions that, when executed by the one or more processors, cause the one or more processors to receive a user authentication request for accessing a first server comprising a management console application. The management console application configured to access management console services to monitor a medical device in a hospital system. The user authentication request comprises a user identifier and a password, and the first server further comprises a local user database and a local authentication system. The memory also causes the one or more processors to determine whether the user identifier exists in the local user database and authenticate the user identifier and the password through the local authentication system when the user identifier exists in the local user database. Otherwise authenticate the user identifier and password through an external authentication system in a second server communicably coupled to the first server. The memory also causes the one or more processors to provide access to the first server when the user identifier and the password are authenticated through either the local authentication system or the external authentication system, otherwise deny access to the first server.
The invention relates to a depression-relieving and nerve-soothing pillow inner which is composed of a replaceable traditional Chinese medicine bag and memory cotton. The replaceable traditional Chinese medicine bag is composed of the following raw material medicines: lavender, jasmine, platycladi seed, polygala root, grassleaf sweelflag rhizome and light wheat. The invention also provides application of the traditional Chinese medicine in preparing a depression-relieving and nerve-soothing medicine. The advantages are that: 1. the selected raw material medicaments are safe and have no side effect. 2. The traditional Chinese medicine components and the proportion thereof of the depression-relieving and nerve-soothing pillow inner provided by the invention are screened by experiments, have the advantage of remarkable effect, can improve sleep, relieve symptoms of anxiety, depression, agitation and excessive fatigue, help a patient to relieve mental burden and excessive mental labor, adjust working state and living state, and ensure that the patient obtains good sleep guarantee quality at night.
This is an open-label Phase 1b/2 clinical study of Samalizumab given in addition to standard induction chemotherapy/consolidation, followed by Samalizumab maintenance, in newly diagnosed acute myeloid leukemia. Patients that are marker negative, as defined based on the Beat AML Master Protocol assignment or with CBF karyotype/interphase cytogenetics/molecular testing defined by presence of t(8;21)(q22;q22) or the molecular equivalent RUNX1/RUNX1T1 fusion transcript or inv(16)(p13q22) or t(16;16)(p13;q22) or the molecular equivalent CBFB/MYH11 fusion transcript based on the Beat AML will receive Samalizumab in combination with induction therapy followed by Samalizumab maintenance.
PROBLEM TO BE SOLVED: To provide a new α-ketoamide derivative composed of a non-peptide α-ketoamide derivative, having excellent chymase inhibiting action and useful as an agent for the prevention and treatment of cardiovascular diseases, etc., of warm-blooded animals. SOLUTION: The objective compound is expressed by formula I [A is a substituted lower alkyl, a lower alkoxy or an aromatic ring; R1 and R2 are each H, a (substituted)alkyl or the like], e.g. N-[2,5-bis(N-benzylcarbamoyl) phenyl]-2-oxo-3-phenylpropanamide. The compound of formula I can be produced by reacting an α-keto-acid halide derivative of formula A-COCO-X (X is a halogen) with an aniline derivative of formula II preferably in a reaction solvent (e.g. tetrahydrofuran) in the presence of an organic base (e.g. 4- dimethylaminopyridine). The amount of the organic base is preferably 0.05-1.0 mol based on 1 mol of the aniline derivative and the reaction temperature is preferably 0-30 deg.C.
The invention discloses a sodium gualenate antiallergic facial cleanser. Per 100g of the facial cleanser comprises 5-40g of the traditional Chinese medicine extracting solution, 0.01-1g of sodium gualenate, 6-20g of mild surfactant, 3-10g of skin nutrient, 2-10g of humectants and 30-80g of purified water. The facial cleanser is a most skin-friendly mild facial cleanser without any stimulating chemical raw materials or any toxic side effect. While effectively cleaning the face, the facial cleanser is mild and skin friendly without irritation, so that the facial cleanser is suitable for the children and the people with sensitive skin. The facial cleanser contains multiple traditional Chinese herbal medicine extracts, comprising the traditional Chinese medicine extractive, sodium gualenate, the mild surfactant, the skin nutrient, the humectants, the purified water and the other assistant components. The facial cleanser is mild, safe and free of irritation and the skin can be cleaned and protected and also can be beautified, especially the facial cleanser is suitable for the people with sensitive skin and allergic symptoms.
PURPOSE:To obtain a low-toxic antimicrobial agent having excellent controlling activity against true fungi, by using FR109615 or its salts as active component. CONSTITUTION:The objective agent contains the compound FR109615 and its salt having controlling action against pathogenic microorganisms, especially pathogenic fungi (e.g. Candida albicans). The active component can be produced by culturing an FR109615-producing strain belonging to Streptomyces genus (e.g. Streptomyces setonii No.7562: FERM P-9444) in a nutrient medium under aerobic condition and separating from the cultured product. The culture is preferably carried out in a deep tank under aerobic condition for mass production. The FR109615 is (1R,2S)-2-aminocyclopentanecarboxylic acid of formula.
Patients complete surveys over 30 minutes about sociodemographic information and perception of immunotherapy, over 10 minutes about expectations of cure, over 10 minutes about anxiety, over 10 minutes about depression, and over 30 minutes about physical well-being. Patients' medical records are reviewed.
Effective inhibition of intestinal lipid uptake is an efficient strategy for the treatment of disorders related to lipid metabolism. Sterol O-acyltransferase 2 (SOAT2) is responsible for the esterification of free cholesterol and fatty acids into cholesteryl esters. We found that intestine-specific SOAT2 knockout (Soat2I-KO) mice was capable to prevent the development of dietary induced obesity due to reduced intestinal lipid absorption. Soat2 siRNA/CS-PLGA nanoparticle system was constructed to enable intestinal delivery and inhibition of Soat2. This nanoparticle system was composed of PLGA-block-PEG and chitosan specifically delivering Soat2 siRNAs into small intestines in mice, effectively inhibit intestinal lipid uptake and resolving obesity. In revealing the underlying mechanism by which intestinal SOAT2 regulating fatty acid uptake, enhanced CD36 ubiquitination degradation was found in enterocytes upon SOAT2 inhibition. Insufficient free cholesterol esterification promoted endoplasmic reticulum stress and recruitment of E3 ligase RNF5 to activate CD36 ubiquitination in SOAT2 knockdown enterocytes. This work demonstrates a potential modulatory function of intestinal SOAT2 on lipid uptake highlighting the therapeutic effect on obesity by targeting intestinal SOAT2, exhibiting promising translational relevance in the siRNA therapeutic-based treatment for obesity.
The Motivational Interview, or MI, (15-30 minutes) was provided after initial substance use disorder assessments but prior to treatment admission. I twas facilitated by a computer generated report and included: an orientation to the session, discussion of the participants' strengths, an agenda setting procedure, a review of concerns, and a session summary. Therapists conveyed empathy, used reflective listening, tried to elicit and reinforce change talk elements, and elicited action steps from the participants.